The randomized, double-blind trial compares TAS-102 with best supportive care (BSC) to investigate the efficacy and safety of TAS-102 when administered to patients who are both unresectable and
The company plans to distribute the product, in 60-count bottles, through multiple online sales channels, independent retailers, and health professionals. Each capsule of For Her Senses contains a
The transaction is subject to approval by Welichem shareholders. Under the agreement, Welichem will receive an initial payment of C$35m and is eligible to receive additional milestone payments
Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET. As a part of the NDA filing, which is based on data from a Phase III
Perrigo is the exclusive marketer and distributor of the product for the store brand over-the-counter (OTC) market in the US. Perrigo expects to begin shipment of the product
The transaction is subject to certain regulatory approvals and is expected to close in the third quarter of 2012. The purchase will be financed with available cash. AptarGroup
The FDA had registered INJEX Pharma, Berlin, and INJEX Pharma US, Miami, and issued approval for the import and sale of INJEX 30 in the US market. The
According to the new agreement, BioFocus, Galapagos’ service division, will use its SilenceSelect platform to deliver validated targets to Ono. Ono works to find modulators for the targets
The extension of the partnership was based on successful antibody discovery work during a research evaluation period. Dyax spokesperson Gustav Christensen said the company is providing Bayer with
A validated ALK assay should be used to assess ALK-positive advanced or metastatic NSCLC in patients. The Xalkori oral monotherapy can be prescribed if the patients are ALK-positive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.